Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Neuroblastoma 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Nivolumab 17Ipilimumab 14pembrolizumab 11Cyclophosphamide 8trametinib 7dabrafenib 6Interleukin-2 6aldesleukin 5Vemurafenib 5Radiotherapy 5sargramostim 4130-nm albumin-bound paclitaxel 4fludarabine 3encorafenib 3binimetinib 3Specimen Handling 3Radiosurgery 3Melphalan 3Granulocyte-Macrophage Colony-Stimulating Factor 3fludarabine phosphate 2Magnetic Resonance Spectroscopy 2Introns 2Infliximab 2Celecoxib 2CTLA-4 Antigen 2Biopsy 2Bevacizumab 2Albumin-Bound Paclitaxel 2yeast-CEA vaccine 1vitespin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Melanoma × Spermine Synthase × Clear all
NCT02145910 2025-05-02

Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases

Thomas Jefferson University

Phase 1 Withdrawn
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡